SMA 200 of Retrophin, Inc.
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
|SPRO Spero Therapeutics, Inc.||NASDAQ||3.77|
|LRN K12 Inc||NYSE > Consumer Services > Other Consumer Services||3.77|
|IAG Iamgold Corporation||NYSE > Basic Industries > Precious Metals||3.78|
|SILC Silicom Ltd||NASDAQ > Technology > Computer Communications Equipment||3.78|
|SUI Sun Communities, Inc.||NYSE > Consumer Services > Real Estate Investment Trusts||3.78|
|SGBX SG Blocks, Inc.||NASDAQ > Consumer Services > RETAIL: Building Materials||3.78|
|RTRX Retrophin, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||3.80|
|ORI Old Republic International Corporation||NYSE > Finance > Property-Casualty Insurers||226.11|
|KREF KKR Real Estate Finance Trust Inc.||NYSE > Consumer Services > Real Estate Investment Trusts||251.20|
|MAG MAG Silver Corporation||NYSEMKT > Basic Industries > Precious Metals||296.35|
|SLF Sun Life Financial Inc.||NYSE > Finance > Life Insurance||430.81|
|AMG Affiliated Managers Group, Inc.||NYSE > Finance > Investment Managers||965.40|
|IOR Income Opportunity Realty Investors, Inc.||NYSEMKT > Consumer Services > Real Estate Investment Trusts||4,830.80|